Evidence map›Paper›PMID 34319442›Full record

Observational studyActa neuropathologica2021

Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.

Charles D Chen, Nelly Joseph-Mathurin, Namita Sinha, Aihong Zhou, Yan Li, Karl Friedrichsen, Austin McCullough, Erin E Franklin, Russ Hornbeck, Brian Gordon and 21 more

Open access · greenAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Acta neuropathologica, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  5. Trial
  6. Longitudinal head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2023
    Trial
  7. The striatum is an early, accurate indicator of amyloid burden using [Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 14 institutions in 5 countries.

Charles D ChenMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Nelly Joseph-Mathurin *Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Namita Sinha *Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.
Aihong Zhou *Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Yan LiDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Karl FriedrichsenDepartment of Ophthalmology and Visual Sciences, Washington University in St. Louis, St. Louis, MO, USA.
Austin McCulloughMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Erin E FranklinDepartment of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.
Russ HornbeckMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Brian GordonMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Vijay SharmaMallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
Carlos CruchagaDepartment of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.
Alison GoateDepartment of Genetics and Genomic Sciences, Ichan School of Medicine at Mount Sinai, New York, NY, USA.
Celeste KarchDepartment of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.
Eric McDadeDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Chengjie XiongDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Randall J BatemanDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Bernardino GhettiDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
John M RingmanDepartment of Neurology, Keck School of Medicine of USC, Los Angeles, CA, USA.
Jasmeer ChhatwalDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Colin L MastersThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia.
Catriona McLeanDepartment of Anatomic Pathology, Alfred Hospital, Melbourne, VIC, Australia.
Tammaryn LashleyUCL Queen Square Institute of Neurology, University College London, London, UK.
Yi SuBanner Alzheimer's Institute, Banner Health, Phoenix, AZ, USA.
Robert KoeppeDepartment of Radiology, University of Michigan, Ann Arbor, MI, USA.
Clifford JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
William E KlunkDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
John C MorrisDepartment of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
Richard J PerrinDepartment of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.
Nigel J Cairns *Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO, USA.
Tammie L S Benzinger *Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, MO, USA. benzingert@wustl.edu.
Washington University in St. Louis · USMallinckrodt (United States) · USBanner Health · USCapital Medical University · CNIndiana University – Purdue University Indianapolis · USKeck Hospital of USC · USMassachusetts General Hospital · USMayo Clinic in Arizona · USNational Hospital for Neurology and Neurosurgery · GBThe Alfred Hospital · AUUniversity of Exeter · GBUniversity of Melbourne · AUUniversity of Michigan–Ann Arbor · USUniversity of Pittsburgh · US

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI CLIFFORD R. JACK · 2016 to 2026
$226.7M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
USCADRC Diversity Supplement PachicanoP30AG066530 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HELENA Chang CHUI, ARTHUR W TOGA · 2020 to 2026
$27.8M
Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
Imaging CoreU01AG032438 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2008 to 2009
$6.1M
PET Imaging of Neuroinflammation in Genetic Alzheimer's DiseaseR01AG052550 · NIA · WASHINGTON UNIVERSITY · PI Beau M Ances, Tammie Lee Smith Benzinger · 2018 to 2026
$4.2M
Quantification of Neuroinflammation inAlzheimer's Disease Using Diffusion BasisSpectrum ImagingR01AG054567 · NIA · WASHINGTON UNIVERSITY · PI BENZINGER, TAMMIE LEE SMITH, WANG, YONG · 2017 to 2021
$3.6M
Antecedent Biomarker Changes in AD: Ordering, Stages, and Implications for TrialsRF1AG053550 · NIA · WASHINGTON UNIVERSITY · PI XIONG, CHENGJIE · 2016 to 2016
$3.4M
NIA NIH HHS K01 AG053474NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066530NIA NIH HHS P50 AG005681NIA NIH HHS R01 AG052550NIA NIH HHS R01 AG054567NIA NIH HHS RF1 AG053550NIA NIH HHS U01 AG032438NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG032438NIA NIH HHS UF1 AG032438NIH HHS K01AG053474NIH HHS P30AG066444, P01AG026276, P01AG03991, UF1AG032438, U19 AG032438, U19 AG024904NIH HHS P30NS098577NIH HHS S10 OD025214NIH HHS U19AG032438NINDS NIH HHS P30 NS098577
6 · The paper itself

Abstract

Pittsburgh compound B (PiB) radiotracer for positron emission tomography (PET) imaging can bind to different types of amyloid-β plaques and blood vessels (cerebral amyloid angiopathy). However, the relative contributions of different plaque subtypes (diffuse versus cored/compact) to in vivo PiB PET signal on a region-by-region basis are incompletely understood. Of particular interest is whether the same staging schemes for summarizing amyloid-β burden are appropriate for both late-onset and autosomal dominant forms of Alzheimer disease (LOAD and ADAD). Here, we compared antemortem PiB PET with follow-up postmortem estimation of amyloid-β burden using stereologic methods to estimate the relative area fraction of diffuse and cored/compact amyloid-β plaques across 16 brain regions in 15 individuals with ADAD and 14 individuals with LOAD. In ADAD, we found that PiB PET correlated with diffuse plaques in the frontal, parietal, temporal, and striatal regions commonly used to summarize amyloid-β burden in PiB PET, and correlated with both diffuse and cored/compact plaques in the occipital lobe and parahippocampal gyrus. In LOAD, we found that PiB PET correlated with both diffuse and cored/compact plaques in the anterior cingulate, frontal lobe (middle frontal gyrus), and parietal lobe, and showed additional correlations with diffuse plaque in the amygdala and occipital lobe, and with cored/compact plaque in the temporal lobe. Thus, commonly used PiB PET summary regions predominantly reflect diffuse plaque burden in ADAD and a mixture of diffuse and cored/compact plaque burden in LOAD. In direct comparisons of ADAD and LOAD, postmortem stereology identified much greater mean amyloid-β plaque burdens in ADAD versus LOAD across almost all brain regions studied. However, standard PiB PET did not recapitulate these stereologic findings, likely due to non-trivial amyloid-β plaque burdens in ADAD within the cerebellum and brainstem-commonly used reference regions in PiB PET. Our findings suggest that PiB PET summary regions correlate with amyloid-β plaque burden in both ADAD and LOAD; however, they might not be reliable in direct comparisons of regional amyloid-β plaque burden between the two forms of AD.

Indexed as

AdultAgedAlzheimer DiseaseAmyloid beta-PeptidesAniline CompoundsCohort StudiesFemaleHumansMaleMiddle AgedPlaque, AmyloidPositron-Emission TomographyThiazoles2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazoleAmyloid beta-PeptidesAniline CompoundsThiazolesAlzheimer diseaseAmyloid-β plaquesPiB PETStereology

Identifiers

PMID34319442
PMCPMC8815340
OpenAlexW3186377521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.